This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ko, B. K. Articles by Ioannides, C. G. Search for Related Content PubMed PubMed Citation Articles by Ko, B. K. Articles by Ioannides, C. G. Related Collections Cancer Immunology Cancer Immunology: Immunotherapy

Clinical Studies of Vaccines Targeting Breast Cancer¹

Departments of Surgical Oncology [B. K. K., H. M. K.], Bioimmunotherapy [J. L. M.], Gynecologic Oncology [K. K., C. L. E., C. G. I.], and Immunology [C. G. I.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Department of Surgery, Walter Reed Army Medical Center, Washington, D. C. 20307 [G. E. P.]; and Department of Oncology, University of Washington, Seattle, Washington 98195 [M. L. D.]

Many clinical studies have been undertaken to assess the therapeutic potential of vaccination and have included a large variety of cancer immunogens. Most of these studies involved patients with metastatic cancer, which is characterized by the most aggressive malignant cells, the longest-lasting disease, and the failure of all standard cytotoxic treatments. The presence of tumor over long periods and the toxicity of previous treatments tend to negatively affect immune responsiveness to tumor antigens presented by the vaccine. In this review, we analyze the ability of past and current vaccine therapies to induce clinical responses in breast cancer. To date, clinical responses have been observed by using vaccines targeting HER-2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen, and carbohydrate antigen given after stem cell rescue. The review concludes with a discussion of possible future directions for vaccine development and applications.

This article has been cited by other articles:

				A. Scardino, M. Alimandi, P. Correale, S. G. Smith, R. Bei, H. Firat, M. G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, et al. A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge Cancer Res., July 15, 2007; 67(14): 7028 - 7036. [Abstract] [Full Text] [PDF]

				G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]

				C. T. Viehl, M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer Ann. Surg. Oncol., July 1, 2005; 12(7): 517 - 525. [Abstract] [Full Text] [PDF]

				K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death Cancer Res., April 1, 2005; 65(7): 2930 - 2937. [Abstract] [Full Text] [PDF]

				F. J. Esteva Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer Oncologist, June 3, 2004; 9(suppl_3): 4 - 9. [Abstract] [Full Text] [PDF]